AIM ImmunoTech

AIMNYSE United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$6.144 M

$0.15 -4.35%

Close of 6 Nov 2026

As of 6 Nov 2026, AIM ImmunoTech (AIM) has a market capitalization of $6.14M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$88.0K

#3572 by revenue

Earnings

-$14.0M

Loss-making

Shares outstanding

30,442,139

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#151In8bioINAB$8.30M
#152Senti BiosciencesSNTI$6.33M
#153AIM ImmunoTechAIM$6.14M
#154CurisCRIS$5.84M
#155Creative Medical TechnologyCELZ$4.63M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of AIM ImmunoTech, worth $10.2K. Grants and option exercises are excluded.

Thomas K. EquelsCEO & President$5.07K
31,675 shares at $0.16 on 23 Oct 2026 · filed 26 Oct 2026
Thomas K. EquelsCEO & President$5.09K
31,250 shares at $0.16 on 22 Oct 2026 · filed 23 Oct 2026

What if AIM ImmunoTech were worth as much as…

Open the what-if tool →

Gold $28.2T

$707,782.53

Per share 4,595,990× higher

Bitcoin $1.53T

$38,296.88

Per share 248,681× higher

Apple $5.02T

$125,725.08

Per share 816,397× higher

Or at a round number

$10.0M $20.0M $50.0M $100.0M

Where these numbers come from

Share counts and financials for AIM ImmunoTech are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.